Nanosphere (NSPH) Gets De Novo Petition from FDA to Market Gram-Positive BC-GP

June 27, 2012 12:34 PM EDT Send to a Friend
Nanosphere, Inc. (Nasdaq: NSPH), reports the U.S. Food and Drug Administration has granted a de novo petition permitting marketing of its Gram-Positive Blood Culture Nucleic Acid Test (BC-GP) on the automated sample-to-result Verigene System.

The BC-GP test notably expands Nanosphere's infectious disease test capabilities to include fast detection of bacteria that can cause deadly bloodstream infections, an increasingly recognized health threat.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment